This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Intellia Therapeutics faces...
Business securities lawsuit

Intellia Therapeutics faces securities lawsuit

Analysis based on 7 articles · First reported Mar 15, 2025 · Last updated Apr 10, 2025

Sentiment
-50
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the news of Coya Therapeutics discontinuing its NTLA-3001 program and cutting its workforce, as evidenced by the 15.14% drop in Coya Therapeutics's stock price. The ongoing securities class action lawsuit by Faruqi & Faruqi further adds to the negative sentiment surrounding Coya Therapeutics.

Biotechnology Legal Services
Event Summary

Faruqi & Faruqi, LLP is investigating Coya Therapeutics, Inc. for potential federal securities law violations. The lawsuit alleges that Coya Therapeutics made false and misleading statements regarding its Phase 1/2 study of NTLA-3001 for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Specifically, Coya Therapeutics allegedly failed to disclose that viral-based editing demand was dwindling, making NTLA-3001 inefficient. On January 9, 2025, Coya Therapeutics announced it would discontinue NTLA-3001 development, focus on other drug candidates, and cut 27% of its workforce, incurring an $8 million charge. This news caused Coya Therapeutics's stock price to fall by 15.14%. Additionally, Laura Sepp-Lorenzino, the Chief Scientific Officer, retired.

Key Actions
85 Coya Therapeutics halted research
80 Faruqi & Faruqi investigated claims Coya Therapeutics
60 Coya Therapeutics announced retirement Laura Sepp-Lorenzino
Entities Involved
stock
Coya Therapeutics
Coya Therapeutics, Inc. is facing a federal securities class action lawsuit for allegedly making false and misleading statements regarding its NTLA-3001 study, leading to a significant drop in its stock price and a workforce reduction.
Importance 100.0 Sentiment -70.0
per
Laura Sepp-Lorenzino
Laura Sepp-Lorenzino, Ph.D., the Chief Scientific Officer of Coya Therapeutics, announced her retirement amidst the company's restructuring and discontinuation of the NTLA-3001 program.
Importance 30.0 Sentiment -10.0
priv
Faruqi & Faruqi
Importance 0.0 Sentiment 0.0
per
James Wilson
Importance 0.0 Sentiment 0.0
Relationships
Faruqi & Faruqi related ↔ James Wilson
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.